Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models

• DOI: 10.1111/j.1464-410x.2012.11127.x
• Publication Date: 2012-05-04T12:46:18Z
• Authors: Viacheslav Iremas...; Murugesan Manoharan; Daniel L. Rosenberg; Mark S. Soloway
• Keywords: Watchful waiting

What's known on the subject? and What does study add? Active surveillance is an established management option for patients with favourable‐risk prostate cancer. However, about 25–30% of active demonstrate biopsy progression within first 3–5 years follow‐up. Although several factors, such as results diagnostic biopsies, are to be associated risk progression, our ability accurately predict this remains limited. Our analysis demonstrated that overall number positive cores in biopsies strongly patients. Furthermore, combined provide more information probability than they do separately. The most important variable affecting progression‐free survival was By 3 surveillance, who had four progressed, while those only one core excellent prognosis. These findings could used improve accuracy assessments prognosis low‐risk cancer help them make informed decisions their treatment. Objective To analyse prognostic importance provided by biopsy, a combination thereof identify particularly high progression. Materials Methods present included 161 at least two biopsies. performed 1 year diagnosis. Further usually took place every 1–2 years. Progression defined presence G leason 4/5 cancer, > or >20% involvement any core. C ox proportional hazards regression examine relationship between characteristics Three distinct statistical models were built using thereof. H arrell's c‐index quantify predictive each multivariate model. Results median follow‐up 3.6 years; 46 (28.6%) progressed. In major factor cores. model based significantly individual biopsy. Patients estimated 5‐year rate 100%. Conclusion total provides